Publications by authors named "Y UEMURA"
Background: The prognostic implications of cerebral microbleeds (CMBs) in patients who undergo transcatheter aortic valve replacement (TAVR) have not been fully elucidated. Therefore, we aimed to investigate the association between the presence of CMBs and adverse outcomes post-TAVR.
Methods: In this single-center retrospective study, we included 124 patients who underwent brain magnetic resonance imaging before TAVR.
Objectives: Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD.
Methods: A post-hoc analysis was performed on prospective data from 48 patients with SSc-ILD in the double-blind, randomized, placebo-controlled DESIRES trial.
Glial cells missing 2 (GCM2) has been identified as an essential factor for parathyroid differentiation, and GCM2 silencing in parathyroid cells decreases calcium-sensing receptor (CaSR) expression. However, the role of GCM2 in parathyroid differentiation from induced pluripotent stem cells (iPSCs) is unclear. Here, we investigated the role of GCM2 in parathyroid differentiation from iPSCs using the Tet-On 3 G system.
View Article and Find Full Text PDFArticle Synopsis
- A study reviewed 106 patients with advanced urothelial carcinoma treated with the antibody-drug conjugate enfortumab vedotin (EV) between 2021 and 2023 to evaluate the impact of treatment-related adverse events (trAEs) on survival outcomes.* -
- The results indicated that 88.7% of patients experienced some form of trAEs, with skin and gastrointestinal issues being the most common, and a landmark analysis suggested that trAEs were linked to longer overall survival, particularly physical trAEs.* -
- The study concluded that managing trAEs and understanding their prognostic value is important for improving the outcomes of EV therapy in these patients, highlighting that physical trAEs were